ArticleBMC neurology2026
Cerebrospinal fluid markers of alzheimer's pathology relate to aMCI among people with HIV.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAs people with HIV survive to older ages, they become more at risk for Alzheimer’s disease (AD) and its precursor, amnestic mild cognitive impairment (aMCI). Memory impairment is also common in other neurocognitive disorders (NDs), including HIV-associated neurocognitive disorders (HAND), which makes it a challenge to diagnose aMCI among PWH. Therefore, we assessed the utility of cerebrospinal fluid (CSF) AD pathology markers in distinguishing aMCI from HAND in PWH by investigating how these markers differentially relate to aMCI.
methodsParticipants included 74 PWH (Mean age = 48 [SD = 8.5]; 87.4% male, 56.5% White) from the National NeuroHIV Tissue Consortium who consented to a lumbar puncture and had CSF biomarker data for Aβ42, p-Tau181, p-Tau181/Aβ42 ratio, neopterin, and neurofilament light chain (NfL) data, as well as completed a neurocognitive battery. Participants were classified as aMCI using Jak/Bondi criteria (if they had impairment (≥ 1.0 standard deviation [SD] below the mean) on ≥ 2 memory outcomes among learning, delayed recall, and recognition, with at least one recognition impairment required). HAND participants had impairment (≥ 1.0 SD below the mean) in ≥ 2 cognitive domains. HIV disease characteristics and demographic covariates were included in separate linear regression models that examined how individual biomarkers relate to diagnostic status.
resultsAmong participants, 43.2% met the criteria for aMCI, 51.3% for HAND, and 34.2% met the criteria for both HAND and aMCI. Greater AD pathology, specifically CSF p-Tau181, was higher in PWH with aMCI compared to PWH without aMCI (F(1,48) = 4.789; p =.034; ηp2 = 0.091). CSF p-Tau181 did not differ by HAND status. While the p-Tau181/Aβ42 ratio was greater among those with an aMCI-like profile among PWH, it did not reach a statistically significant difference. No other biomarker significantly differed by group status.
conclusionsResults suggest CSF p-Tau181 is indicative of an aMCI-like cognitive profile among PWH, and may be a biologically distinct subgroup of PWH with HAND. More precise diagnosis of aMCI will allow earlier planning; however, more long-term studies are needed to determine the direction of the current results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.